<DOC>
	<DOCNO>NCT00082823</DOCNO>
	<brief_summary>RATIONALE : Intravenous VEGF Trap may stop growth solid tumor non-Hodgkin 's lymphoma stopping blood flow cancer . PURPOSE : This phase I trial study side effect VEGF Trap treat patient relapsed refractory advance solid tumor non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Intravenous VEGF Trap Treating Patients With Relapsed Refractory Advanced Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety tolerability intravenous VEGF Trap patient relapse refractory advance solid tumor non-Hodgkin 's lymphoma . Secondary - Determine steady-state pharmacokinetics drug patient . - Determine ability drug bind circulate vascular endothelial growth factor patient . - Determine whether antibody drug develop patient . - Determine , preliminarily , ability repeat dos drug alter tumor growth vascular permeability patient . OUTLINE : This open-label , multicenter , extension study . Patients receive VEGF Trap* IV 1 hour day 1 . Courses repeat every 14 day absence disease progression unacceptable toxicity . NOTE : *Patients receive drug dose receive MSKCC-03137 ( VGFT-ST-0202 ) Patients follow monthly 3 month . PROJECTED ACCRUAL : A total 25 patient accrue study within 3-6 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonHodgkin 's lymphoma OR primary metastatic solid tumor locate least one follow site : Liver Soft tissue Pelvis Other site suitable delayed contrastenhancing MRI Relapsed refractory disease Failed conventional therapeutic option AND amenable exist therapeutic option Must complete active phase ( study visit 9 ) MSKCC03137 ( VGFTST0202 ) without experience doselimiting toxicity No prior concurrent CNS metastasis ( brain leptomeningeal ) No new neurological symptom treatment MSKCC03137 ( VGFTST0202 ) PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic No severe uncontrolled hematologic condition Hepatic Not specify Renal No severe uncontrolled renal condition Cardiovascular No severe uncontrolled cardiovascular condition Pulmonary No severe uncontrolled pulmonary condition Other No severe uncontrolled gastrointestinal , immunologic , musculoskeletal condition No medical psychiatric condition adverse social circumstance would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublebarrier contraception 3 month study treatment PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent epoetin alfa , filgrastim ( GCSF ) , sargramostim ( GMCSF ) Chemotherapy Not specify Endocrine therapy No concurrent adrenal corticosteroid , except lowdose replacement therapy No concurrent systemic hormonal contraceptive agent Radiotherapy Not specify Surgery Not specify Other No concurrent nonsteroidal antiinflammatory drug , include cyclooxygenase2 ( COX2 ) inhibitors No concurrent anticoagulant antiplatelet drug , include warfarin , heparin , aspirin Concurrent lowdose ( i.e. , 1 mg ) warfarin maintain patency venous access device allow No concurrent standard investigational agent malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>recurrent vaginal cancer</keyword>
	<keyword>stage IVA vaginal cancer</keyword>
	<keyword>stage IVB vaginal cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent penile cancer</keyword>
	<keyword>stage IV penile cancer</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>recurrent vulvar cancer</keyword>
	<keyword>stage IVB vulvar cancer</keyword>
	<keyword>distal urethral cancer</keyword>
	<keyword>proximal urethral cancer</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>